Phase 1 Small Cell Lung Carcinoma Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1
A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Boehringer Ingelheim300 enrolled12 locationsNCT04429087
Recruiting
Phase 1Phase 2
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC110 enrolled48 locationsNCT04938817
Recruiting
Phase 1Phase 2
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.118 enrolled4 locationsNCT07407933
Recruiting
Phase 1
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Large Cell Neuroendocrine Carcinoma of the LungSmall Cell Lung CarcinomaNeuroendocrine Prostate Cancer+1 more
Novartis Pharmaceuticals116 enrolled5 locationsNCT07006727
Recruiting
Phase 1Phase 2
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
Small Cell Lung CancerSmall Cell Lung Carcinoma
Memorial Sloan Kettering Cancer Center53 enrolled1 locationNCT04199741
Recruiting
Phase 1
A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer
Small Cell Lung Carcinoma (SCLC)Neuroendocrine Neoplasms
Boehringer Ingelheim12 enrolled1 locationNCT05963867
Recruiting
Phase 1
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
NeoplasmsSmall Cell Lung Carcinoma (SCLC)Glioblastoma, Adult
Chipscreen Biosciences, Ltd.102 enrolled2 locationsNCT06902350